NCF1 and non-small cell lung carcinoma: Next, we performed pharmacological experiments with DPI (an NAD(P)H Oxidase (NOX) inhibitor) and Apo (a p47phox inhibitor), and DPI inhibits decrease of cell viability in PB01-treated NSCLC cells, but not Apo (Fig. 4e).